This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burvenich, I. Articles by Slegers, G. Search for Related Content PubMed PubMed Citation Articles by Burvenich, I. Articles by Slegers, G.

In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131–Labeled Monoclonal Antibody 14C5 in a Non–Small Cell Lung Cancer and Colon Carcinoma Model

Authors' Affiliations: ¹ Laboratory of Radiopharmacy, ² Department of Biomedical Research, Flanders Institute of Biotechnology (VIB), and ³ N. Goormaghtigh Institute of Pathology, University of Ghent, Ghent, Belgium

Requests for reprints: Ingrid Burvenich, Laboratory of Radiopharmacy, University of Ghent, B-9000 Ghent, Belgium. Phone: 32-9-2648063; Fax: 32-9-2207424; E-mail: ingrid.burvenich{at}ugent.be.

Purpose: The monoclonal antibody (mAb) 14C5 is a murine IgG1 directed against a yet undefined molecule involved in cell substrate adhesion found on the surface of malignant breast cancer tissue. mAb 14C5 is able to inhibit cell substrate adhesion and invasion of breast cancer cells in vitro. In normal tissues as well as in the stroma surrounding in situ carcinomas of the breast, no expression of the antigen 14C5 occurs. The aim of this study was to investigate the in vitro and in vivo targeting properties of ¹²³I- and ¹³¹I-labeled mAb 14C5 as a novel agent for radioimmunodetection and radioimmunotherapy.

Experimental Design: Internalization of mAb 14C5 was investigated with ¹²⁵I-labeled mAb 14C5 and by confocal laser scanning microscopy. Biodistribution studies of ¹³¹I-labeled mAb 14C5 and planar gamma imaging were done in nude mice bearing an A549 (non–small cell lung carcinoma) or a LoVo (colon carcinoma) tumor.

Results: Internalization studies with both A549 and LoVo cells showed that ¹²⁵I-labeled mAb 14C5 is slowly internalized with 30% of the initially bound mAb 14C5 internalized after 2 hours at 37°C. Internalization of mAb 14C5 could be visualized with confocal laser scanning microscopy. In vivo, radioisotope uptake peaked at 24 hours for both tumor models (n = 5) with no significant difference in percentage of injected dose/g tissue (A549 10.4 ± 0.8 and LoVo 9.3 ± 0.8). Via planar gamma camera imaging, A549 lung tumors as well as LoVo colon tumors could be clearly visualized.

Conclusions: The in vitro and in vivo targeting properties of ¹²³I- and ¹³¹I-labeled mAb 14C5 are promising and could provide a new antibody-based agent for radioimmunodetection and radioimmunotherapy of patients bearing antigen 14C5–expressing tumors.

This article has been cited by other articles:

				I. Burvenich, S. Schoonooghe, L. Vervoort, C. Dumolyn, E. Coene, L. Vanwalleghem, J. Van Huysse, M. Praet, C. Cuvelier, N. Mertens, et al. Monoclonal antibody 14C5 targets integrin {alpha}v{beta}5 Mol. Cancer Ther., December 1, 2008; 7(12): 3771 - 3779. [Abstract] [Full Text] [PDF]

				L. O. T. Gainkam, L. Huang, V. Caveliers, M. Keyaerts, S. Hernot, I. Vaneycken, C. Vanhove, H. Revets, P. De Baetselier, and T. Lahoutte Comparison of the Biodistribution and Tumor Targeting of Two 99mTc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT J. Nucl. Med., May 1, 2008; 49(5): 788 - 795. [Abstract] [Full Text] [PDF]